中药治疗肺炎支原体感染的实验研究进展  

Experimental Research Progress of Traditional Chinese Medicine in Mycoplasma Pneumoniae Infection

作　　者：赵晓阳 姜永红[1] ZHAO Xiaoyang;JIANG Yonghong(Pediatric Department,Longhua Hospital Affiliated to Shanghai University of TCM,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院儿科,上海200032

出　　处：《辽宁中医杂志》2019年第4期874-877,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金项目(81671509);上海市市属博士学科点建设基金(B201503);上海中医药大学附属龙华医院国家中医临床研究基地"龙医团队;龙医学者"(培育)建设<龙医儿科肺系疾病研究团队>(LYTD-15)

摘　　要：肺炎支原体是儿童社区获得性呼吸道感染的主要病原体,发病率有逐年上升趋势。其容易引起哮喘及慢性咳嗽,且可引起肺外并发症,甚至导致重症肺炎、难治性肺炎支原体肺炎。近年来,越来越多的报道显示,中药对肺炎支原体具有一定的抑制作用,且可调节免疫,改善循环,降低耐药性,预防复发。文章旨在对近30年来,中医药对抗肺炎支原体感染的实验研究作一综述。Mycoplasma pneumoniae is the main pathogens in children with community acquired respiratory tract infections and the incidence rate is increasing year by year. It is easy to cause asthma and chronic cough,and can lead to extra-pulmonary complications,and even severe pneumonia,refractory mycoplasma pneumoniae pneumonia. In recent years,more and more reports have shown that traditional Chinese medicine has an inhibitory effect on mycoplasma pneumoniae,which can regulate immunity,improve circulation,reduce drug resistance and prevent recurrence. This paper aims to review the experimental study of traditional Chinese medicine against mycoplasma pneumoniae infection in the past 30 years.

关 键 词：肺炎支原体 中药 实验研究 

分 类 号：R375.2[医药卫生—病原生物学]